Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allogeneic transplant for FLT3 - ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant

1 Jan 2019

Abstract excerpt

FMS-like tyrosine kinase 3 ( FLT3) mutations are one of the most frequently encountered genetic alterations in acute myeloid leukemia (AML), and are generally associated with unfavorable outcomes. Several tools are currently available to provide an accurate prognosis for patients with these mutations, including FLT3 mutation type (internal tandem duplication versus tyrosine kinase domain), mutation allelic ratio...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31700594
DOI: 10.1177/2040620719882666

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allogeneic transplant for FLT3 - ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplantPMID 31700594Read ↗

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSemantic proximity Read ↗

Current Approaches to Transplantation for FLT3-ITD AML.Semantic proximity Read ↗

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Semantic proximity Read ↗

FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AMLSemantic proximity Read ↗

An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape.Semantic proximity Read ↗

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging ControversiesSemantic proximity Read ↗

FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.Semantic proximity Read ↗

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 InhibitorsSemantic proximity Read ↗

Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total Therapy.Semantic proximity Read ↗

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity Read ↗

Fms -like tyrosine kinase 3 positive acute myeloid leukemia.Semantic proximity Read ↗

Targeting FLT3 to treat leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.